Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model
To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol: control: vehicle, carcinogen: 0.05% of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2010/380937 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562061033340928 |
|---|---|
| author | José Sereno Belmiro Parada Flávio Reis Fernanda X. Cunha Edite Teixeira-Lemos Patrícia Garrido Rui Pinto Petronila Rocha-Pereira Paula Neto José Ruivo Paulo Rodrigues-Santos Sara Nunes Alfredo Mota Arnaldo Figueiredo Frederico Teixeira |
| author_facet | José Sereno Belmiro Parada Flávio Reis Fernanda X. Cunha Edite Teixeira-Lemos Patrícia Garrido Rui Pinto Petronila Rocha-Pereira Paula Neto José Ruivo Paulo Rodrigues-Santos Sara Nunes Alfredo Mota Arnaldo Figueiredo Frederico Teixeira |
| author_sort | José Sereno |
| collection | DOAJ |
| description | To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol: control: vehicle, carcinogen: 0.05% of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), CEL: 10 mg/kg/day of the selective COX-2 inhibitor Celebrex, preventive CEL (CEL+BBN-P), and curative CEL (BBN+CEL-C) groups. Although tumor growth was markedly inhibited by the preventive application of CEL, it was even aggravated by the curative treatment. The incidence of gross bladder carcinoma was: control 0/8(0%), BBN 13/20(65%), CEL 0/8(0%), CEL+BBN-P 1/8(12.5%), and BBN+CEL-C 6/8(75%). The number and volume of carcinomas were significantly lower in the CEL+BBN-P versus BBN, accompanied by an ample reduction in hyperplasia, dysplasia, and papillary tumors as well as COX-2 immunostaining. In spite of the reduction of tumor volumes in the curative BBN+CEL-C group, tumor malignancy was augmented. An anti-inflammatory and antioxidant profile was encountered only in the group under preventive treatment. In conclusion, preventive, but not curative, celecoxib treatment promoted a striking inhibitory effect on bladder cancer development, reinforcing the potential role of chemopreventive strategies based on cyclooxygenase 2 inhibition. |
| format | Article |
| id | doaj-art-83e66919082944d79e6f5a73126bd5fd |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-83e66919082944d79e6f5a73126bd5fd2025-02-03T01:23:32ZengWileyMediators of Inflammation0962-93511466-18612010-01-01201010.1155/2010/380937380937Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat ModelJosé Sereno0Belmiro Parada1Flávio Reis2Fernanda X. Cunha3Edite Teixeira-Lemos4Patrícia Garrido5Rui Pinto6Petronila Rocha-Pereira7Paula Neto8José Ruivo9Paulo Rodrigues-Santos10Sara Nunes11Alfredo Mota12Arnaldo Figueiredo13Frederico Teixeira14Institute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalService of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalPharmacology & Pharmacotoxicology Unit, Pharmacy School of Lisbon, 1649-003 Lisboa, PortugalInstitute for Molecular and Cellular Biology, Porto University, 4150 Porto, PortugalService of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, PortugalService of Anatomic Pathology, Coimbra University Hospital, 3000-075 Coimbra, PortugalImmunology & Oncology Laboratory, Centre for Neuroscience and Cell Biology, 3004-517 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalDepartment of Urology & Renal Transplantation, Coimbra University Hospital, 3000-075 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalInstitute of Pharmacology & Experimental Therapeutics, IBILI, Medicine Faculty, Sub-Unit 1 (Polo III), Coimbra University, 3000-354 Coimbra, PortugalTo evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol: control: vehicle, carcinogen: 0.05% of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), CEL: 10 mg/kg/day of the selective COX-2 inhibitor Celebrex, preventive CEL (CEL+BBN-P), and curative CEL (BBN+CEL-C) groups. Although tumor growth was markedly inhibited by the preventive application of CEL, it was even aggravated by the curative treatment. The incidence of gross bladder carcinoma was: control 0/8(0%), BBN 13/20(65%), CEL 0/8(0%), CEL+BBN-P 1/8(12.5%), and BBN+CEL-C 6/8(75%). The number and volume of carcinomas were significantly lower in the CEL+BBN-P versus BBN, accompanied by an ample reduction in hyperplasia, dysplasia, and papillary tumors as well as COX-2 immunostaining. In spite of the reduction of tumor volumes in the curative BBN+CEL-C group, tumor malignancy was augmented. An anti-inflammatory and antioxidant profile was encountered only in the group under preventive treatment. In conclusion, preventive, but not curative, celecoxib treatment promoted a striking inhibitory effect on bladder cancer development, reinforcing the potential role of chemopreventive strategies based on cyclooxygenase 2 inhibition.http://dx.doi.org/10.1155/2010/380937 |
| spellingShingle | José Sereno Belmiro Parada Flávio Reis Fernanda X. Cunha Edite Teixeira-Lemos Patrícia Garrido Rui Pinto Petronila Rocha-Pereira Paula Neto José Ruivo Paulo Rodrigues-Santos Sara Nunes Alfredo Mota Arnaldo Figueiredo Frederico Teixeira Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model Mediators of Inflammation |
| title | Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model |
| title_full | Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model |
| title_fullStr | Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model |
| title_full_unstemmed | Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model |
| title_short | Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model |
| title_sort | preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model |
| url | http://dx.doi.org/10.1155/2010/380937 |
| work_keys_str_mv | AT josesereno preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT belmiroparada preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT flavioreis preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT fernandaxcunha preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT editeteixeiralemos preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT patriciagarrido preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT ruipinto preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT petronilarochapereira preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT paulaneto preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT joseruivo preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT paulorodriguessantos preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT saranunes preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT alfredomota preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT arnaldofigueiredo preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel AT fredericoteixeira preventivebutnotcurativeefficacyofcelecoxibonbladdercarcinogenesisinaratmodel |